Orchid Pharma Ltd
NSE:ORCHPHARMA

Watchlist Manager
Orchid Pharma Ltd Logo
Orchid Pharma Ltd
NSE:ORCHPHARMA
Watchlist
Price: 1 778.6 INR -1.05%
Market Cap: 90.2B INR
Have any thoughts about
Orchid Pharma Ltd?
Write Note

Orchid Pharma Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Orchid Pharma Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Orchid Pharma Ltd
NSE:ORCHPHARMA
Total Liabilities & Equity
â‚ą15.5B
CAGR 3-Years
8%
CAGR 5-Years
-13%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Total Liabilities & Equity
â‚ą467.3B
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Total Liabilities & Equity
â‚ą346.6B
CAGR 3-Years
10%
CAGR 5-Years
7%
CAGR 10-Years
9%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Total Liabilities & Equity
â‚ą881.2B
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
11%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Total Liabilities & Equity
â‚ą150.9B
CAGR 3-Years
3%
CAGR 5-Years
2%
CAGR 10-Years
8%
M
Mankind Pharma Ltd
NSE:MANKIND
Total Liabilities & Equity
â‚ą119.6B
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Orchid Pharma Ltd
Glance View

Market Cap
90.2B INR
Industry
Pharmaceuticals

Orchid Pharma Ltd. engages in the development, manufacture, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company is headquartered in Chennai, Tamil Nadu. The firm is involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals. The company has a multi-therapeutic presence across segments like anti-infectives, anti-inflammatory, central nervous system (CNS), cardiovascular segment (CVS), nutraceuticals and other oral and sterile products. Its pharmaceutical solutions include active pharmaceutical ingredients (APIs) and finished dosage forms. The company offers APIs, including Cephalosporins-Orals, Cephalosporins-Injectables, Veterinary Products and Non-Antibodies. Its formulations include Cefixime Capsules, Acarbose Tablets, Acarbose Tablets, Clozapime Tablets, Clopidogrel Tablets, Desloratadine Tablets and Cefoperazone and Sulbactam for Injection, among others. Its subsidiaries include Orchid Europe Limited, Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals, Inc., among others.

ORCHPHARMA Intrinsic Value
1 261.31 INR
Overvaluation 29%
Intrinsic Value
Price

See Also

What is Orchid Pharma Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
15.5B INR

Based on the financial report for Mar 31, 2024, Orchid Pharma Ltd's Total Liabilities & Equity amounts to 15.5B INR.

What is Orchid Pharma Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
-13%

Over the last year, the Total Liabilities & Equity growth was 27%. The average annual Total Liabilities & Equity growth rates for Orchid Pharma Ltd have been 8% over the past three years , -13% over the past five years .

Back to Top